All Articles

• FDA Approves Keytruda for First-Line Treatment of Non–Small-Cell Lung Cancer (TPS ≥1%)
• FDA Advises Women to Avoid Pregnancy for Only 2 Months After Final Dose of Soltamox

A focus on training nonclinical patient navigators whose role is to provide cancer information, resources, and support to remove barriers to care.

There are many excuses for not writing an abstract. You may even be hesitant to share your work. However, there are even more reasons to share how and why you embrace your navigation.

Nurses and navigators play a crucial role in teaching patients about genetics and genomics, as well as in gathering the vital information necessary to actually carry out genetic testing and allowing patients to take control of their genetic inheritance.

At the 2018 AONN+ Annual Conference, attendees heard a rapid-fire rundown of some of the most newsworthy, and sometimes controversial, topics in cancer care.

Lawmakers want lower list prices, but insurers are at fault for mismanaging plans

On April 4, 2019, the US Food and Drug Administration (FDA) expanded the indication of palbociclib (Ibrance; Pfizer), a kinase inhibitor, in combination with specific endocrine therapies for men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This is the first hormonal-based therapy to be approved for men.

Navigators have the unique opportunity to learn from each other through the sharing of findings from their research projects at the Academy of Oncology Nurse & Patient Navigators (AONN+) Annual Conference.

Ms Miller speaks with JONS about patient success stories and The Mesothelioma Center’s ability to enhance the patient experience.